Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
The new hub, which brings Avantor solutions closer to regional customers and strengthens global supply chain capabilities, will be fully operational early next year
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Subscribe To Our Newsletter & Stay Updated
